India’s anti-obesity drug market has witnessed a fourfold growth over the last five years, surging from ₹133 crore in March 2021 to ₹576 crore by March 2025. The remarkable rise is driven by the growing prevalence of lifestyle diseases and increasing affordability among urban consumers seeking medical solutions for weight management.

Key Highlights

Semaglutide Leads Market Boom

• Novo Nordisk’s oral semaglutide pill Rybelsus is the largest growth driver, capturing 69% of the market.

• Sales of Rybelsus rose from ₹11 crore in March 2022 to ₹397 crore in March 2025.

• Novo Nordisk is also preparing to launch Wegovy, its semaglutide injectable, soon in India.

New Entrants Fuel Demand

• Eli Lilly’s Mounjaro (tirzepatide), launched recently at ₹3,500 per weekly injection, has gained popularity as an affordable weight-loss option.

• With cardiovascular benefits, Mounjaro is expanding acceptance for prescription-based weight management.

Rising Demand Linked to Lifestyle Changes

• India has nearly 100 million obese adults, with comorbidities such as diabetes, hypertension, and heart disease.

• Patients are increasingly willing to invest in anti-obesity drugs for sustained health benefits.

• According to PharmaTrac’s Sheetal Sapale, “Rybelsus propelled the growth of this market. Mounjaro is expected to supplement and accelerate this growth.”

Market Share of Other Molecules

• Orlistat: ₹72 crore

• Dulaglutide: ₹72 crore

• Liraglutide: ₹34 crore

With increasing awareness, improved access, and innovative drug launches, India’s anti-obesity market is poised for sustained growth. Both Rybelsus and Mounjaro are expected to dominate prescriptions in the coming quarters, with more players likely to enter the fray.